We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $49.63, moving -1.16% from the previous trading session. This move lagged the S&P 500's daily loss of 0.39%. Elsewhere, the Dow gained 0.12%, while the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the pharmaceutical had lost 7.07% in the past month. In that same time, the Medical sector gained 5.94%, while the S&P 500 gained 4.06%.
Wall Street will be looking for positivity from AZN as it approaches its next earnings report date. In that report, analysts expect AZN to post earnings of $0.53 per share. This would mark year-over-year growth of 17.78%. Meanwhile, our latest consensus estimate is calling for revenue of $7.01 billion, up 5.2% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2 per share and revenue of $26.22 billion, which would represent changes of +14.29% and +7.53%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for AZN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.77% lower. AZN is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note AZN's current valuation metrics, including its Forward P/E ratio of 25.07. This valuation marks a premium compared to its industry's average Forward P/E of 13.8.
Investors should also note that AZN has a PEG ratio of 1.79 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.25 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 172, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
Astrazeneca (AZN - Free Report) closed the most recent trading day at $49.63, moving -1.16% from the previous trading session. This move lagged the S&P 500's daily loss of 0.39%. Elsewhere, the Dow gained 0.12%, while the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the pharmaceutical had lost 7.07% in the past month. In that same time, the Medical sector gained 5.94%, while the S&P 500 gained 4.06%.
Wall Street will be looking for positivity from AZN as it approaches its next earnings report date. In that report, analysts expect AZN to post earnings of $0.53 per share. This would mark year-over-year growth of 17.78%. Meanwhile, our latest consensus estimate is calling for revenue of $7.01 billion, up 5.2% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2 per share and revenue of $26.22 billion, which would represent changes of +14.29% and +7.53%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for AZN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.77% lower. AZN is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note AZN's current valuation metrics, including its Forward P/E ratio of 25.07. This valuation marks a premium compared to its industry's average Forward P/E of 13.8.
Investors should also note that AZN has a PEG ratio of 1.79 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.25 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 172, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.